Company intelligence / Profile preview

TECLens

Stamford, Connecticut, United Statesteclens.com ↗

Ownership: Private
Development stage: Phase 1

Overview

TECLens has successfully completed a pilot study in keratoconus patients demonstrating safety and efficacy of its qCXL platform. The company is now advancing to proof-of-concept and early-stage clinical trials for non-invasive refractive vision correction, with a primary focus on presbyopia. The approach uses personalized UV light dosing with real-time ultrasound monitoring to reshape the cornea without incisions or ablation.

Therapeutic areas: Ophthalmology
Modalities: DeviceNon-pharmacological therapy (corneal cross-linking)
Industry: Therapeutic Medical Devices

Partnerships

Johnson & Johnson Innovation–JJDC Inc.Validcare (CRO partner)

Beyond the preview

Go deeper on TECLens.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TECLens.